A single‑arm Phase 2 study published in Nature Communications evaluated daratumumab, an anti‑CD38 antibody, in systemic lupus erythematosus (SLE) patients and reported clinical responses alongside mechanistic immune changes. Investigators documented reductions in autoantibody levels and improvement on multiple disease activity measures in a refractory SLE cohort. The data provide proof‑of‑concept that plasma‑cell targeting can modulate disease in autoimmunity and justify further controlled testing. Sponsors and investigators emphasized safety monitoring given daratumumab’s established immunomodulatory effects in oncology and the need to define the patient subsets most likely to benefit.